Hiroyuki Okuzawa Representative Director, President & COO Koji Ogawa Executive Officer, Head of Global Corporate Planning & Management, CFO Ken Takeshita Head of R&D Unit PLAY LIST from the beginning FY2023 Financial Results Presentation Forward Looking Statements 1. FY2023 Financial Results Overview of FY2023 Results Revenue Core Operating Profit. Profit Attributable to Owners of the Company Revenue: Business Units (incl. Forex Impact) Revenue: Major Products in Japan 2. Business Update Progress towards “Maximize 3ADCs” Revenue Performance in Each Region (US, EU) Performance in Each Region (Japan, ASCA) Strategic Collaboration with Merck & Co., Inc., Rahway, NJ,USA Progress towards “Profit growth for current business and products” LIXIANA : Growth in Each Country/Region LIXIANA : Growth in Japan Other Initiatives in Japan Other Regional Initiatives Progress towards “Create shared value with stakeholders” FY2023 Annual Dividend Forecast 3. R&D Update FY2023 R&D major achievements Progress towards “Maximize 3ADCs” DESTINY-PanTumor02 study Expanding treatment opportunities beyond Japan, US and EU Progress in FY2023: NSCLC TROPION-Lung10 study TROPION-Lung14 study Progress in FY2023: breast cancer Progress in FY2023 Combination studies with internal asset Progress towards “Profit growth for current business and products” Progress in FY2023 IDeate-Lung03 study Ph2 study targeting multiple solid tumors Progress in FY2023 Progress in FY2023(2) Other Progress in FY2023 ASCO 2024 ASCO Highlight 2024: IR conference call News Flow FY2024 News Flow 4. 5Year Business Plan Update Strategic Pillars for the 5Year Business Plan (FY2021 FY2025) 5Year Business Plan : Progress in FY2021 FY2023 5Year Business Plan : Progress in FY2021 FY2023(2) Estimate for FY2025 KPIs Estimated Oncology Revenue Estimated R&D Expenses Well-balanced Investment for Growth and Shareholder Returns Forecast of FY2025 KPIs Daiichi Sankyo will contribute to the enrichment of quality of life around the world5.2024年度 業績予想 5. FY2024 Forecast FY2024 Forecast FY2024 Annual Dividend Forecast Flexible Acquisition of Own Shares @6.Appendix 3ADCs launch plan Major R&D Milestones (ENHERTU) Major R&D Milestones (Dato-DXd) Major R&D Milestones (HER3 DXd, I DXd , DS 6000) Major R&D Milestones (Next Wave) Major R&D Pipeline: 5DXd ADCs Major R&D Pipeline: Next Wave @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Back Next